

Title (en)  
BLOOD GLUCOSE CONTROL SYSTEM

Title (de)  
SYSTEM FÜR BLUTZUCKERKONTROLLE

Title (fr)  
SYSTÈME DE RÉGULATION DE LA GLYCÉMIE

Publication  
**EP 4042436 A4 20231004 (EN)**

Application  
**EP 20872651 A 20201002**

Priority

- US 201962910970 P 20191004
- US 201962911017 P 20191004
- US 201962911143 P 20191004
- US 202062987842 P 20200310
- US 202063037472 P 20200610
- US 2020042195 W 20200715
- US 2020042198 W 20200715
- US 2020042269 W 20200716
- US 2020054130 W 20201002

Abstract (en)  
[origin: WO2021067767A1] Blood glucose control systems and ambulatory medical devices that provide therapy to a subject are disclosed. Disclosed systems and devices can implement one or more features that improve the user experience, such as software update techniques that avoid interrupting delivery of therapy, gesture-based control of therapy delivery, automatic resumption of therapy after a user-initiated pause, improved alarm management, display of autonomously calculated dosing recommendations, wide area network connectivity, and security features.

IPC 8 full level  
**G16H 20/17** (2018.01); **A61M 5/142** (2006.01); **A61M 5/172** (2006.01); **G16H 40/60** (2018.01)

CPC (source: AU EP IL)  
**A61B 5/14532** (2013.01 - EP IL); **A61B 5/4839** (2013.01 - EP IL); **A61M 5/14244** (2013.01 - EP IL); **A61M 5/172** (2013.01 - EP IL); **A61M 5/1723** (2013.01 - EP IL); **G06F 8/65** (2013.01 - EP IL); **G06F 8/656** (2018.02 - AU); **G16H 15/00** (2018.01 - AU EP IL); **G16H 20/17** (2018.01 - EP IL); **G16H 40/40** (2018.01 - AU EP IL); **G16H 40/60** (2018.01 - AU); **G16H 40/63** (2018.01 - EP IL); **G16H 40/67** (2018.01 - AU EP IL); **G16H 50/20** (2018.01 - EP IL); **A61M 5/1408** (2013.01 - AU); **A61M 5/14244** (2013.01 - AU); **A61M 5/1723** (2013.01 - AU); **A61M 2005/1401** (2013.01 - AU); **A61M 2005/14208** (2013.01 - AU EP IL); **A61M 2205/18** (2013.01 - AU EP IL); **A61M 2205/3303** (2013.01 - EP IL); **A61M 2205/3553** (2013.01 - AU EP IL); **A61M 2205/3569** (2013.01 - AU EP IL); **A61M 2205/3584** (2013.01 - AU EP IL); **A61M 2205/3592** (2013.01 - AU EP IL); **A61M 2205/502** (2013.01 - EP IL); **A61M 2205/505** (2013.01 - AU); **A61M 2205/609** (2013.01 - AU); **A61M 2230/201** (2013.01 - AU EP IL)

C-Set (source: AU)  
**A61M 2230/201** + **A61M 2230/005**

Citation (search report)

- [XII] US 2018185587 A1 20180705 - BRAUKER JAMES H [US], et al
- [XII] US 2019214124 A1 20190711 - MOUGIAKAKOU STAVROULA [CH], et al
- [XII] US 2017053101 A1 20170223 - BOOTH ROBERT C [US], et al
- [E] WO 2021011738 A1 20210121 - BETA BIONICS INC [US], et al
- See also references of WO 2021067856A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**WO 2021067767 A1 20210408**; AU 2020356952 A1 20220414; AU 2020358856 A1 20220414; CA 3151777 A1 20210408; CA 3151782 A1 20210408; CN 114868200 A 20220805; CN 114902344 A 20220812; DE 112020004762 T5 20220811; DE 112020004780 T5 20220901; EP 4042436 A1 20220817; EP 4042436 A4 20231004; EP 4042441 A1 20220817; EP 4042441 A4 20231011; IL 291671 A 20220501; IL 291746 A 20220501; JP 2022551265 A 20221208; JP 2023503792 A 20230201; MX 2022003961 A 20220721; MX 2022003962 A 20220721; WO 2021067856 A1 20210408

DOCDB simple family (application)  
**US 2020054025 W 20201002**; AU 2020356952 A 20201002; AU 2020358856 A 20201002; CA 3151777 A 20201002; CA 3151782 A 20201002; CN 202080084028 A 20201002; CN 202080084498 A 20201002; DE 112020004762 T 20201002; DE 112020004780 T 20201002; EP 20872387 A 20201002; EP 20872651 A 20201002; IL 29167122 A 20220324; IL 29174622 A 20220328; JP 2022520424 A 20201002; JP 2022520425 A 20201002; MX 2022003961 A 20201002; MX 2022003962 A 20201002; US 2020054130 W 20201002